Serum levels of albumin-amyloid beta complexes are decreased in Alzheimer's disease

Geriatrics and Gerontology International

Volumn 14, Issue 3, 2014, Pages 716-723

  Yamamoto, Keiichi ^a   Shimada, Hiroyuki ^a   Koh, Hideo ^a   Ataka, Suzuka ^a   Miki, Takami ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Albumin; Alzheimer's disease; Amyloid ; Biomarkers; Serum

Indexed keywords

ALBUMIN; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; TAU PROTEIN; BIOLOGICAL MARKER; SERUM ALBUMIN;

AGED; ALBUMIN BLOOD LEVEL; ALZHEIMER DISEASE; AMYLOID BETA BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; IMMUNOPRECIPITATION; MALE; MINI MENTAL STATE EXAMINATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; BLOOD; CASE CONTROL STUDY; JAPAN; METABOLISM; PREVALENCE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; APOLIPOPROTEIN E4; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; JAPAN; MALE; PREVALENCE; SERUM ALBUMIN;

EID: 84904975199     PISSN: 14441586     EISSN: 14470594     Source Type: Journal    
DOI: 10.1111/ggi.12147     Document Type: Article

References (31)

1. Wimo A, Winblad B, Jönsson L. The worldwide societal costs of dementia: estimates for 2009. Alzheimers Dement 2010; 6: 98-103.
2. Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997; 18: 351-357.
3. Sperling RA, Aisen PS, Beckett LA etal. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 280-292.
4. Salmon DP, Lange KL. Cognitive screening and neuropsychological assessment in early Alzheimer's disease. Clin Geriatr Med 2001; 17: 229-254.
5. Becker RE, Greig NH, Giacobini E. Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices? J Alzheimers Dis 2008; 15: 303-325.
6. Selkoe DJ. Resolving controversies on the path to Alzheimer's therapeutics. Nat Med 2011; 17: 1060-1065.
7. Blennow K, Zetterberg H, Minthon L etal. Longitudinal stability of CSF biomarkers in Alzheimer's disease. Neurosci Lett 2007; 419: 18-22.
8. van der Vlies AE, Verwey NA, Bouwman FH etal. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease. Neurology 2009; 72: 1056-1061.
9. Forsberg A, Engler H, Almkvist O etal. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2008; 29: 1456-1465.
10. Gomez-Isla T, West HL, Rebeck GW etal. Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimer's disease. Ann Neurol 1996; 39: 62-70.
11. Lindsay AF, Mitchell FB, Louis E etal. Statement on use of apolipoprotein E testing for Alzheimer disease. American College of Medical Genetics/American Society of Human Genetics Working Group on ApoE and Alzheimer disease. JAMA 1995; 274: 1627-1629.
12. Scheuner D, Eckman C, Jensen M etal. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 1996; 2: 864-870.
13. Tamaoka A, Fukushima T, Sawamura N etal. Amyloid beta protein in plasma from patients with sporadic Alzheimer's disease. J Neurol Sci 1996; 141: 65-68.
14. Schupf N, Tang MX, Fukuyama H etal. Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease. Proc Natl Acad Sci U S A 2008; 105: 14052-14057.
15. van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM. Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol 2006; 5: 655-660.
16. Wang YJ, Zhou HD, Zhou XF. Clearance of amyloid-beta in Alzheimer's disease: progress, problems and perspectives. Drug Discov Today 2006; 11: 931-938.
17. Mawuenyega KG, Sigurdson W, Ovod V etal. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 2010; 330: 1774.
18. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 2001; 98: 8850-8855.
19. DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 2002; 295: 2264-2267.
20. Boada M, Ortiz P, Anaya F etal. Amyloid-targeted therapeutics in Alzheimer's disease: use of human albumin in plasma exchange as a novel approach for Abeta mobilization. Drug News Perspect 2009; 22: 325-339.
21. Biere AL, Ostaszewski B, Stimson ER, Hyman BT, Maggio JE, Selkoe DJ. Amyloid beta-peptide is transported on lipoproteins and albumin in human plasma. J Biol Chem 1996; 271: 32916-32922.
22. Kay AD, May C, Papadopoulos NM etal. CSF and serum concentrations of albumin and IgG in Alzheimer's disease. Neurobiol Aging 1987; 8: 21-25.
23. McKhann G, Drachman DA, Folstein MF, Katzman R, Prince D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services task force on Alzheimer's disease. Neurology 1984; 34: 939-944.
24. Eto M, Watanabe K, Ishii K. A rapid flat gel isoelectric focusing method for the determination of apolipoprotein E phenotypes and its application. Clin Chim Acta 1985; 149: 21-28.
25. Yamazaki A, Matsumoto H, Asai M, Takamatsu J. Comparative study of improved BCP method in serum albumin and its utility. Seibutsu Shiryo Bunseki 2005; 28: 259-266.
26. Schuller E, Tömpe L, Delasnerie N. Simultaneous determination of albumin and IgG in serum and CSF: comparison of electro-immunodiffusion and immunonephelometry. Biomedicine 1975; 23: 189-192.
27. Menard SW. Applied Logistic Regression Analysis, 2nd edn. Thousand Oaks, CA: Sage Publications, 2001; 75-78.
28. Henneman WJ, Vrenken H, Barnes J, Sluimer IC etal. Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease. Neurology 2009; 73: 935-940.
29. Era S, Kuwata K, Imai H, Nakamura K, Hayashi T, Sogami M. Age-related change in redox state of human serum albumin. Biochim Biophys Acta 1995; 1247: 12-16.
30. Guerin-Dubourg A, Catan A, Bourdon E, Rondeau P. Structural modifications of human albumin in diabetes. Diabetes Metab 2012; 38 (2): 171-178.
31. Rabinovici GD, Furst AJ, O'Neil JP etal. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology 2007; 68: 1205-1212.